ALLEGRO-DVT
14.12.2022 15:01:44 CET | Business Wire | Press release
Labwise the leader in digital TV conformance testing announces the availability of StreamWise-ATSC its latest digital TV test suites that enable testing of ATSC 3.0 (NEXTGEN TV) receivers and TV sets to ensure their conformance with ATSC 3.0 TV service features.
Labwise, a recognized leader in digital TV device testing services, was acquired by Allegro DVT, the worldwide leader in video codec compliance streams, in June 2022. Labwise has been operating as an independent, impartial, and objective testing house since 2004, providing professional digital TV test suites and services to major TV OEMs, digital TV broadcasters and operators across Europe.
Anne Schelle, Managing Director of Pearl TV commented “ATSC 3.0 brings many new broadcast TV features through multiple advanced technologies to enhance the user viewing experience. The industry needs to ensure that devices are interoperable and properly implement the ATSC 3.0 features though trusted conformance testing. We welcome this announcement from Labwise, as an established and trusted player in digital TV testing which will further accelerate the adoption of NEXTGEN TV across the USA and other markets.”
Nouar Hamze, CEO of Allegro DVT added " Today’s launch of StreamWise-ATSC is at the heart of our new strategy to extend our Digital TV testing products to cover ATSC 3.0. Labwise, the latest addition of Allegro DVT group of companies, has gained tremendous expertise and become a trusted and impartial test house in multiple markets across Europe. The entire ATSC 3.0 ecosystem including device manufacturers and broadcasters, will benefit from StreamWise-ATSC by having access to feature-rich, reliable and trusted test suites."
StreamWise-ATSC by Labwise enables the testing of NEXTGEN TV broadcast service profile. These test suites allow device manufacturers to verify the compliance of products, or have devices tested as a service at Labwise laboratory to cover all the features and help tackle the technological complexity brought by the ATSC 3.0 standard.
The laboratory test environment is targeted for the device black box testing and is provided with optional HW environment for broadcast modulation. The test system includes the ATSC 3.0 test plan and the test case information i.e., test configuration, procedures, and specification references to make it easy for the tests engineer to perform the tests. The test streams are provided in playout formats (ROUTE/DASH and MMT).
More precisely these test suites cover multiple features such as:
Video |
|
Subtitles and captions |
|
Audio |
|
Delivery
|
|
Advanced Emergency Alerting |
|
About Pearl TV
Pearl TV is a business organization of U.S. broadcast companies with a shared interest in exploring forward-looking broadcasting opportunities, including innovative ways of promoting local broadcast TV content and developing digital media and wireless platforms for the broadcast industry. Pearl’s membership, comprising more than 820 TV stations, includes eight of the largest broadcast companies in America: Cox Media Group, Graham Media Group, Gray Television, Hearst Television Inc., Nexstar Media Group, Sinclair Broadcast Group, the E.W. Scripps Company, and TEGNA Inc.
About Allegro DVT
Allegro DVT is a world leading provider of digital video technology solutions including compliance streams. Labwise operates as an independent, impartial, and objective testing house providing professional digital TV test services to major TV OEMs, digital TV broadcasters and operator across Europe.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005107/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom